Title Author Journal Date
Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial Atreya et al The Lancet Gastroenterology and Hepatology October 2020
The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis
View PDF
Schmitt et al Journal of Crohn’s and Colitis October 2019
Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis
View PDF
Atreya et al Digestive and Liver Disease June 2018
Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis
View PDF
Atreya et al Journal of Crohn’s and Colitis November 2016
Treatment of ulcerative colitis patients by local application of the Toll like Receptor-9 agonist DIMS0150
View PDF
Löfberg et al Gastrointestinal & Digestive System December 2014
Immunomodulatory oligonucleotides inhibit neutrophil migration by decreasing the surface expression of interleukin-8 and leukotriene B4 receptors.
View PDF
Admyre et al Immunology July 2014
Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients
View PDF
Kuznetsov et al BMC Gastroenterology April 2014
Topical Treatment with the Toll-like Receptor Agonist DIMS0150 Has Potential for Lasting Relief of Symptoms in Patients with Chronic Active Ulcerative Colitis by Restoring Glucocorticoid Sensitivity
View PDF
Musch et al Inflammatory Bowel Diseases May 2012
Inflammatory bowel disease classification through multigene analysis: fact or fiction?
View PDF
Petra von Stein Expert Review of Molecular Diagnostics February 2009
Neither Hide Nor Hair: The Difficulty of Identifying Useful Disease Biomarkers
View PDF
Editorial Gastroenterology April 2008
Multigene Analysis Can Discriminate Between Ulcerative Colitis, Crohn’s Disease, and Irritable Bowel Syndrome
View PDF
Von Stein et al Gastroenterology February 2008
The dioxin/aryl hydrocarbon receptor mediates downregulation of osteopontin gene expression in a mouse model of gastric tumourigenesis
View PDF
Kuznetsov et al Oncogene February 2005